K

Knight Therapeutics Inc
TSX:GUD

Watchlist Manager
Knight Therapeutics Inc
TSX:GUD
Watchlist
Price: 5.25 CAD 0.38% Market Closed
Market Cap: 529.2m CAD
Have any thoughts about
Knight Therapeutics Inc?
Write Note

Knight Therapeutics Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Knight Therapeutics Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
K
Knight Therapeutics Inc
TSX:GUD
Cash from Financing Activities
-CA$53.9m
CAGR 3-Years
-2%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Canopy Growth Corp
TSX:WEED
Cash from Financing Activities
CA$137m
CAGR 3-Years
-48%
CAGR 5-Years
-52%
CAGR 10-Years
19%
Sundial Growers Inc
NASDAQ:SNDL
Cash from Financing Activities
-CA$43.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Cash from Financing Activities
-$1.1m
CAGR 3-Years
57%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Cash from Financing Activities
$252m
CAGR 3-Years
15%
CAGR 5-Years
287%
CAGR 10-Years
N/A
C
Curaleaf Holdings Inc
CNSX:CURA
Cash from Financing Activities
-$22.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Knight Therapeutics Inc
Glance View

Market Cap
530.1m CAD
Industry
Pharmaceuticals

Knight Therapeutics Inc engages in acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. The company is headquartered in Montreal, Quebec and currently employs 660 full-time employees. The company went IPO on 2014-02-28. The firm's principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. The Company’s products include BIJUVA Estradiol and Progesterone capsule, IMVEXXY Estradiol vaginal inserts, IBSRELA Tenapanor tablets, TRELSTAR Prostate Triptorelin, TRELSTAR Endometriosis Triptorelin, ILUVIEN Fluocinolone acetonide, Nerlynx Neratinib Tablets, Nerlynx Patient Checklist, Nerlynx Prescriber Checklist, Burinex Bumetanide, Probuphine Buprenorphine implant, Movantik Naloxegol and Neuragen. The company owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Its subsidiaries operates under United Medical, Biotoscana Farma and Laboratorio LKM.

GUD Intrinsic Value
4.95 CAD
Overvaluation 6%
Intrinsic Value
Price
K

See Also

What is Knight Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
-53.9m CAD

Based on the financial report for Sep 30, 2024, Knight Therapeutics Inc's Cash from Financing Activities amounts to -53.9m CAD.

What is Knight Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
0%

Over the last year, the Cash from Financing Activities growth was -249%. The average annual Cash from Financing Activities growth rates for Knight Therapeutics Inc have been -2% over the past three years .

Back to Top